BSX logo

Boston Scientific Corp

BSX

Build a strategy around BSX

Accountable AI Logo

Boston Scientific Corp AI Insights

Informational only. Not investment advice.
As of 2025-12-08

Snapshot

  • Goodwill of 18.2B is 78% of equity (23.4B) with negative tangible book value (-2.0B) - acquisition-heavy model creates impairment risk.[Goodwill]
  • Operating margin TTM 19.2% vs industry median -5.0% - rare profitable player in largely unprofitable medtech peer group.[Operating Margin TTM]
  • FCF TTM 3.6B (19% margin) on 5.2% capex intensity funds R&D (10% of revenue) without debt reliance.[Free Cash Flow TTM]

Watch Triggers

  • Operating Margin TTM: Falls below 17%Margin compression signals pricing pressure or integration issues - premium valuation requires margin expansion.
  • Goodwill: Impairment charge announcedWith negative tangible book, any goodwill impairment directly hits equity and signals overpayment for acquisitions.
  • Free Cash Flow TTM: FCF margin drops below 15%Cash generation funds M&A strategy without dilution - deterioration limits growth optionality.

Bull Case

Dominant profitability in unprofitable industry: 19.2% operating margin vs -5% median creates pricing power moat. 69% gross margin funds 10% R&D spend.

Operating Margin TTMGross Margin TTMR&D TTM

Cash generation machine: 3.6B FCF (78% conversion from operating cash flow) with low capex needs (5%) enables M&A optionality without dilution.

Free Cash Flow TTMCapital Expenditure TTMCash Flow TTM

Bear Case

Valuation stretched: P/E 45x vs industry median 32x and P/S 7.3x vs 1.9x median prices in perfection. Any margin miss punishes stock.

PE RatioPS Ratio

Acquisition risk: 18.2B goodwill (78% of equity) from serial M&A. Integration failures or write-downs would devastate negative tangible book.

GoodwillTangible Book ValueCommon Stockholders Equity

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
55%

Leverage BSX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

FCF growth will outpace revenue as R&D leverage improves post-acquisition integration.

1-3ymed
  • R&D at 10% of revenue vs 12%+ historical
  • Operating leverage on 19.3B revenue base
  • Debt/equity 0.51 allows continued M&A
FCF margin 19% TTM vs 14% net margin5Y EPS CAGR 41% exceeds revenue growthInterest coverage 11x (EBIT/interest)

Valuation Context

Caveats

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.